Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled AZD1222 COVID-19 Vaccine Booster
NCT05007275Phase 1Unknown
- Sponsor
- Imperial College London
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by Imperial College London. Primary endpoint: Safety, tolerability and reactogenicity profile. Status: unknown.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05007275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007275.